– Neurogastrx, a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced the successful completion of a $60m Series B crossover round led by Vivo Capital.
– Other new investors participating in the Series B round include RTW Investments, Samsara BioCapital and Marshall Wace, joining 5AM Ventures, venBio and OrbiMed Advisors.
– Proceeds from the financing will be used to advance the company’s pipeline of GI therapies for serious conditions that impact millions of people yet are not effectively treated.

– RayzeBio, Inc. announced a $108m Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.
– Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others.
– The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated.
– With over $258m of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.

– Scientia Vascular, a rapidly growing commercial company focused on helping save patients’ lives with a suite of interventional medical devices, has raised $50M of growth equity financing from Vivo Capital, a Palo Alto, CA-headquartered global healthcare investment firm.
– The financing will be used to accelerate sales, marketing, and new product development in both its core neurovascular stroke market as well as adjacent markets in peripheral vascular and interventional oncology.
– The company has leveraged its novel microfabrication technology platform to launch a portfolio of highly differentiated neurovascular products used at leading comprehensive and primary stroke centers in the United States.

– Esco Lifesciences announced the close of an over-subscribed US$200m Series A and Crossover round.
– The financing was led by Vivo Capital and Novo Holdings A/S, with participation from new investors including China Investment Corporation, Singapore-based global investor EDBI, a reputable, long-term institutional investor, and other sophisticated investors.
– Esco Lifesciences, a leading provider of life sciences tools and services, is poised to benefit from the sustained growth of the healthcare and biopharma industries in Asia and globally.

– Sera Prognostics, Inc. from Salt Lake City develops a blood-based biomarker test to predict the risk of preterm birth.
– Series E $100m round brings company valuation to more than $1b.
– The round was led by Vivo Capital, aMoon Fund, Parian Global and others, with participation from existing investors Anthem, Inc., and Blue Ox Healthcare Partners.
– The new investment will be aimed at commercializing its PreTRM® testing, accelerating the development of its pipeline of biomarker tests to predict other major conditions of pregnancy, and developing testing capacity for over 3 million annual pregnancies that are candidates for its PreTRM® Test in the United States.

– Ronovo Surgical, an emerging medtech company focused on innovating minimally invasive (MIS) and digital surgery to address the tremendous needs of the Chinese surgical market, recently announced successful closing of Series A financing.
– The Series A financing was co-led by Matrix Partners China and Vivo Capital, with strong, continued support from seed investor Lilly Asia Ventures (LAV) and participation from GGV Capital.
– Developed by renowned surgeons, medtech veterans and robotics experts, Ronovo was founded in Shanghai in 2019 to establish a transformative technology platform that democratizes MIS and digital surgery in the vastly underserved Chinese surgical market.
– By focusing on the three pillars of simplicity, precision, and intelligence, Ronovo is positioning itself as a gateway to China for cutting edge MIS and digital surgery technology companies from around the world.

– Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints today announced the closing of a $73 million Series B1 and B2 financing.
– The round was led by Oceanpine Capital with participation from additional new investors including Octagon Capital and Sphera Healthcare, and existing investors, including Northern Light Venture Capital and Vivo Capital.
– In conjunction with this round of financing, Oceanpine CEO and managing partner Dave Chenn joins the Immune-Onc Board of Directors.

– Fortis Therapeutics from San Diego is developing novel antibody-drug conjugate FOR46 for late-stage multiple myeloma and metastatic castration-resistant prostate cancer.
– The company closed a $40m Series A financing cofunded by Avalon Ventures, Bregua Corporation, Lilly Asia Ventures, Osage University Partners, Vivo Capital, the Myeloma Investment Fund, the venture philanthropy fund of the Multiple Myeloma Research Foundation (MMRF), and Fulcrum 2020, LLC.
– The new investment will be used to advance FOR46 in clinical trials for the treatment of relapsed or refractory multiple myeloma and metastatic castration-resistant prostate cancer.

– Ossium Health is a therapeutics company that leverages stem cell science to improve treatment for patients with blood and immune diseases.
– The company raised $63m in Series B funding.
– The round was co-led by General Catalyst and Vivo Capital with participation from previous investors First Round Capital, Manta Ray Ventures, and XYZ Capital.
– The new investment will be used to develop stem cell therapies for patients with life-threatening blood and immune diseases.

– Ventyx is an Encinitas, California-based clinical-stage biotechnology company advancing a broad pipeline of potent and selective small-molecule drug candidates to treat inflammatory diseases and autoimmune disorders.
– The company raised $114m in Series C funding.
– The round was led by venBio Partners alongside new investors, including Third Point, RTW Investments, LP, Janus Henderson Investors, Wellington Management, OrbiMed, Surveyor Capital (a Citadel company), Farallon Capital, Vivo Capital, Logos Capital, Qiming Venture Partners USA, Cormorant Asset Management, and participation from founding investor New Science Ventures.

– BlossomHill Therapeutics, a biopharmaceutical company focusing on oncology and autoimmune disorders, has raised $71m in a Series A financing round.
– Cormorant Asset Management LLC led this round and is joined by Hercules BioVentures Partners LLC, OrbiMed Advisors, and Vivo Capital as co-leads.
– In conjunction with the financing, Bihua Chen of Cormorant Asset Management, George J. Lee, Ph.D., of Hercules BioVentures Partners, and Carl L Gordon, Ph.D., CFA, of OrbiMed Advisors joined the company’s Board of Directors.